Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DGNKY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AAJ8D6-Mc-Val-Cit-MMAE
|
|||||
| Synonyms |
AAJ8D6 Mc Val Cit MMAE
Click to Show/Hide
|
|||||
| Organization |
RemeGen Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
|
|||||
| Antibody Name |
AAJ8D6
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 85.49% (Day 21) | Positive MET expression (MET+++/++) | ||
| Method Description |
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (1.1 mg/kg) via the tail vein on Day 0.
|
||||
| In Vivo Model | Gastric cancer PDX model (PDX: LU2535) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 21) | Positive MET expression (MET+++/++) | ||
| Method Description |
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.
|
||||
| In Vivo Model | Gastric cancer PDX model (PDX: GA0045) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 21) | Positive MET expression (MET+++/++) | ||
| Method Description |
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3.3 mg/kg) via the tail vein on Day 0.
|
||||
| In Vivo Model | Gastric cancer PDX model (PDX: LU2535) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 21) | Positive MET expression (MET+++/++) | ||
| Method Description |
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.
|
||||
| In Vivo Model | Gastric cancer PDX model (PDX: LU2535) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 22.00% (Day 21) | Positive MET expression (MET+++/++) | ||
| Method Description |
Inoculate mice with MKN-45 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (0.75 mg/kg) via the tail vein on Day 0.
|
||||
| In Vivo Model | MKN-45 CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 70.00% (Day 21) | Positive MET expression (MET+++/++) | ||
| Method Description |
Inoculate mice with MKN-45 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (1.5 mg/kg) via the tail vein on Day 0.
|
||||
| In Vivo Model | MKN-45 CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.00% (Day 21) | Positive MET expression (MET+++/++) | ||
| Method Description |
Inoculate mice with MKN-45 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.
|
||||
| In Vivo Model | MKN-45 CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.